Literature DB >> 16388387

Scandia--a potential biomaterial?

H M T U Herath1, L Di Silvio, J R G Evans.   

Abstract

Biocompatibility is a pre-requisite for all biomaterials used for medical application. During the last two decades significant advances have been made in the development of novel materials and selection and use of these materials has been directly dependent upon their biocompatibility. Several materials containing calcium or titanium cations demonstrate biocompatibility and are routinely used in various forms within the human body. Due to its position in the periodic table, scandium in the form of its oxide scandia (Sc(2)O(3)) was studied as the first stage of a wider exploration of the biocompatibility of ceramics. A commercial human osteoblast-like cell line (HOS TE 85) was used to study the biocompatibility of both sintered and abraded scandia surfaces. Scanning electron microscopy was used to examine cell adhesion, the MTT assay was used to measure cell metabolic function and the alamarBlue for the assessment of proliferation. Although the results are only preliminary findings, qualitative observations showed that both sintered and abraded surfaces favoured cell adhesion to the same extent. Quantitatively, a significant increase in cell proliferation was observed on Sc(2)O(3) compared to Thermanox, tissue culture control. Furthermore, Sc(2)O(3) has been shown to be non-toxic, able to be maintain cell viability and support cell growth and proliferation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16388387     DOI: 10.1007/s10856-005-4760-1

Source DB:  PubMed          Journal:  J Mater Sci Mater Med        ISSN: 0957-4530            Impact factor:   3.896


  10 in total

1.  Bone matrix mRNA expression in differentiating fetal bovine osteoblasts.

Authors:  K Ibaraki; J D Termine; S W Whitson; M F Young
Journal:  J Bone Miner Res       Date:  1992-07       Impact factor: 6.741

Review 2.  Biomaterials: a forecast for the future.

Authors:  L L Hench
Journal:  Biomaterials       Date:  1998-08       Impact factor: 12.479

Review 3.  Current trends in biocompatibility testing.

Authors:  C J Kirkpatrick; F Bittinger; M Wagner; H Köhler; T G van Kooten; C L Klein; M Otto
Journal:  Proc Inst Mech Eng H       Date:  1998       Impact factor: 1.617

4.  Use of dyes and radioisotopic markers in cytotoxicity tests.

Authors:  S I Schlager; A C Adams
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

5.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

6.  Are MG-63 and HOS TE85 human osteosarcoma cell lines representative models of the osteoblastic phenotype?

Authors:  J Clover; M Gowen
Journal:  Bone       Date:  1994 Nov-Dec       Impact factor: 4.398

7.  In vitro response of osteoblasts to hydroxyapatite-reinforced polyethylene composites.

Authors:  L Di Silvio; M Dalby; W Bonfield
Journal:  J Mater Sci Mater Med       Date:  1998-12       Impact factor: 3.896

Review 8.  Biocompatibility of surgical-grade dense polycrystalline alumina.

Authors:  P S Christel
Journal:  Clin Orthop Relat Res       Date:  1992-09       Impact factor: 4.176

9.  Human bone tissue formation in diffusion chamber culture in vivo by bone-derived cells and marrow stromal fibroblastic cells.

Authors:  R Gundle; C J Joyner; J T Triffitt
Journal:  Bone       Date:  1995-06       Impact factor: 4.398

10.  Microculture tetrazolium assays: a comparison between two new tetrazolium salts, XTT and MTS.

Authors:  C J Goodwin; S J Holt; S Downes; N J Marshall
Journal:  J Immunol Methods       Date:  1995-02-13       Impact factor: 2.303

  10 in total
  1 in total

1.  Antiproliferative Properties of Scandium Exopolysaccharide Complexes on Several Cancer Cell Lines.

Authors:  Javier Muñoz-Garcia; Mattia Mazza; Cyrille Alliot; Corinne Sinquin; Sylvia Colliec-Jouault; Dominique Heymann; Sandrine Huclier-Markai
Journal:  Mar Drugs       Date:  2021-03-23       Impact factor: 5.118

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.